IP Library Granted Patent US 8,916,544
Granted Patent B2
US 8,916,544 · App. 12/671,994 · Granted Dec 23, 2014

Hybrid SCFA-hydroxyl-derivatized monosaccharides, methods of synthesis, and methods of treating disorders

Inventors: Kevin J. Yarema (Woodstock, MD); Udayanath Aich (Cambridge, MA); Christopher Thomas Campbell (Baltimore, MD); Srinivasa-Gopalan Sampathkumar (New Delhi, IN); Sean S. Choi (Columbia, MD); Michael Adam Meledeo (San Antonio, TX); Christopher Weier (Baltimore, MD)
Assignee: The Johns Hopkins University
C07H13/04C07H7/027C07H5/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,916,544
App. No.
12/671,994
Granted
Dec 23, 2014
Kind
B2
Abstract

Described herein are fatty acid carbohydrate-hydroxyl-hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.

Claims (17)

1. A compound of formula I, or pharmaceutically acceptable salt thereof:

wherein,

R 1 is H and each of R 2 , R 3 and R 4 is independently —C(O)(CH 2 ) n CH 3 wherein each n is independently an integer from 1-18; and

R is alkyl or alkenyl, each of which is optionally substituted with 1-4 substituents selected from acyl, oxo, azido, aryl, —OC(O)alkyl, or —SC(O)alkyl.

2. A compound of formula II or formula IV, or pharmaceutically acceptable salt thereof:

wherein,

R 1 is H and each of R 2 , R 3 and R 4 is independently —C(O)(CH 2 ) n CH 3 wherein each n is independently an integer from 1-18; and

R is alkyl or alkenyl, each of which is optionally substituted with 1-4 substituents selected from acyl, oxo, azido, aryl, halogen, —OC(O)alkyl, or —SC(O)alkyl.

3. The compound of claim 2 , wherein each of R 2 , R 3 and R 4 is —C(O)(CH 2 ) 2 CH 3 .

4. The compound of claim 2 , wherein R is alkyl or a substituted alkyl which may be substituted by oxo, azido, aryl, halogen, —OC(O)alkyl, or —SC(O)alkyl.

5. The compound of claim 1 , of formula III, or pharmaceutically acceptable salt thereof:

wherein,

R 1 is H and each of R 2 , R 3 and R 4 is independently —C(O)(CH 2 ) n CH 3 wherein each n is independently an integer from 1-18; and

R is alkyl or alkenyl, each of which is optionally substituted with 1-4 substituents selected from acyl, oxo, azido, aryl, OC(O)alkyl, or —SC(O)alkyl.

6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

7. The composition of claim 6 , further comprising an additional therapeutic agent.

8. A kit comprising an effective amount of a compound of claim 1 in unit dosage form, together with instructions for administering the compound to a subject suffering from or susceptible to a cancer disease or disorder or symptoms thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 15, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044448/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2011
From: YAREMA, KEVIN J.; AICH, UDAYANATH; CAMPBELL, CHRISTOPHER T.; SAMPATHKUMAR, SRINIVASA-GOPALAN; CHOI, SEAN S.; MELEDEO, MICHAEL A.; WEIER, CHRISTOPHER
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 026281/0508 →
Continuity (2)
Provisional Application 60963966 · Aug 8, 2007
Related Publication 20110206734A1 · Aug 25, 2011